Search Results

You are looking at 231 - 240 of 2,708 items for :

  • Refine by Access: All x
Clear All
Full access

Current Surveillance After Treatment is Not Sufficient for Patients With Rectal Cancer With Negative Baseline CEA

Dingcheng Shen, Xiaolin Wang, Heng Wang, Gaopo Xu, Yumo Xie, Zhuokai Zhuang, Ziying Huang, Juan Li, Jinxin Lin, Puning Wang, Meijin Huang, Yanxin Luo, and Huichuan Yu

sustained negative CEA during surveillance, whereas the other 26 (41.3%) in the CEA-turn group had elevated CEA during surveillance before the recurrent disease was confirmed. Interestingly, when we stratified the overall recurrence outcomes by local and

Full access

The Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma

Leona Holmberg and David G. Maloney

complete remission, the disease may become life-threatening. For many patients, the current standard of care involves salvage chemotherapy and autologous hematopoietic stem cell transplantation (ASCT). Successful outcome depends on chemosensitivity at the

Full access

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian Oehler, Arnel M. Pallera, Mrinal Patnaik, Keith Pratz, Iskra Pusic, Michal G. Rose, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory, and Hema Sundar

associated with higher molecular response rates to imatinib. 17 – 20 While some studies have demonstrated a trend toward better survival outcomes with e14a2 transcript, 18 , 19 in other studies the type of transcript did not have any significant impact on

Full access

Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk

Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault, and Armen G. Aprikian

patients from the first evidence of PCa (surgery date, radiation therapy date, ADT initiation, or diagnosis) beginning January 1996 through the end of follow-up. Outcomes Five types of CVD events (incident or fatal) following GnRH agonists or

Full access

Factors Affecting Genetic Consultation in Adolescent and Young Adult Patients With Sarcoma

Grace E. McKay, Anna L. Zakas, Fauzia Osman, and Amanda Parkes

Primary Outcomes Of the 87 AYA patients with sarcoma identified in our study, only 22% (n=19) had documentation of a discussion about genetics with an oncology provider. There was no statistically significant difference in genetic discussion

Full access

HSR21-070: Feasibility of Tracking Digital Activity, Sleep, and Patient-Reported Outcomes (PROs) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Undergoing an In-Class Transition From Parenteral Bortezomib-Based Therapy to Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the Ongoing Community-Based United States (US) MM-6 Study (NCT03173092)

Kirsten Stuber, Habte A. Yimer, Karin Choquette, Sudhir Manda, Jennifer Clayton, Saulius Girnius, Joshua Richter, Presley Whidden, Kimberly Bogard, Dasha Cherepanov, and Stephen J. Noga

(QoL) and improving outcomes. We evaluated the feasibility of digital actigraphy (monitoring activity/rest) and electronic PRO (ePRO) data collection using wearable and mobile devices in an older MM pt population (median age 73 years). Methods

Full access

Delivering on the Promise of Patient-Centered Care

Patricia A. Ganz

Despite our success in improving survival outcomes in patients with cancer, the words “you have cancer” are still terrifying. These 3 words immediately conjure up the threat of death and the physical and emotional suffering associated with cancer

Full access

NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care

Robert W. Carlson, Jillian L. Scavone, Wui-Jin Koh, Joan S. McClure, Benjamin E. Greer, Rashmi Kumar, Nicole R. McMillian, and Benjamin O. Anderson

mature and organized health care infrastructure. They make no recommendations about how resource expenditures should be prioritized to achieve the greatest clinical benefit and outcome. Most of the currently available clinical practice guidelines, such as

Full access

Volume 19 (2021): Issue Suppl_1 (Nov 2021): The Cancer Center Cessation Initiative Working Groups: Improving Oncology Care and Outcomes by Including Tobacco Treatment

Full access

CLO19-034: The Clinical Outcomes of Next-Generation Sequencing Testing at a Community Oncology Practice

Christie Hancock and Jacob Bitran

Background: The value of next-generation sequencing (NGS) tests is dependent on how it changes clinical management, if at all. There are not any guidelines on when a physician should obtain testing; what certain genetic variations can be clinically, meaningfully intervened on; and if this active drug is financially practical. A NGS test ideally should identify a targetable mutational profile that leads to a treatment that can be obtained and produces lasting responses. We reviewed the NGS testing practices at our community hospital. Methods: Patients in our oncology clinic that underwent NGS testing of their tumor were reviewed. Specifically, the patient’s age, gender, diagnosis, date of diagnosis, previous lines of treatment, date of NGS testing, and reported molecular targets were recorded. Details of the changes in clinical management based on the NGS and survival time after the NGS test was ordered were also analyzed. Results: Forty-three patient cases were reviewed that had NGS testing obtained between the years 2014–2015 and 2017. Eighteen patients were males and 25 were females. Median age was 60 years. Most common tumor type was breast; 3 were triple-negative and 6 were only hormone-receptor positive. Second most common type was colorectal. NGS changed management in 12 cases. Two patients were able to enter a clinical trial and the other 10 had therapeutic changes based on protein or mRNA overexpression. Median time of change in management to survival in these patients was 7 months. Thirty-seven patients died; overall time from ordering of test to death was 7 months. Overall time of ordering test to survival for all patients was 8 months. Conclusions: NGS gathers a significant amount of information of a patient’s cancer, but this information is difficult to interpret in the clinical setting. Twenty-eight percent of our patients had a change in treatment, but this did not translate into lasting responses compared to other patients. Furthermore, the responses that were seen may have not been related to the therapeutic interventions, but intrinsic tumor biology. It is important to be aware of the clinical utility in ordering these tests for both the physician and patient.